Meeting
2018 ASCO Annual Meeting
NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.
Authors
Sarah Patricia Blagden
University of Oxford, Oxford, United Kingdom
Sarah Patricia Blagden , T.R. Jeffry Evans , Essam Ahmed Ghazaly , Chathunissa Gnanaranjan , Aimery De Gramont , Josep Tabernero , Jordan Berlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03428958
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3617)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3617
Abstract #
TPS3617
Poster Bd #
109a
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
First Author: T.R. Jeffry Evans
Poster
2021 Gastrointestinal Cancers Symposium
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).
First Author: Andrew L. Coveler
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando